Optas LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Optas LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 2,597 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.

A number of other hedge funds have also modified their holdings of GILD. Jennison Associates LLC bought a new stake in Gilead Sciences in the fourth quarter valued at $87,163,000. Resonant Capital Advisors LLC boosted its stake in shares of Gilead Sciences by 16.2% in the 4th quarter. Resonant Capital Advisors LLC now owns 17,482 shares of the biopharmaceutical company’s stock valued at $1,615,000 after purchasing an additional 2,441 shares in the last quarter. Catalina Capital Group LLC grew its holdings in shares of Gilead Sciences by 25.6% in the 4th quarter. Catalina Capital Group LLC now owns 4,844 shares of the biopharmaceutical company’s stock worth $447,000 after purchasing an additional 987 shares during the last quarter. Princeton Global Asset Management LLC increased its position in shares of Gilead Sciences by 400.0% during the 4th quarter. Princeton Global Asset Management LLC now owns 500 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 400 shares in the last quarter. Finally, HHM Wealth Advisors LLC lifted its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.4 %

Gilead Sciences stock opened at $97.99 on Wednesday. The company has a market cap of $122.12 billion, a price-to-earnings ratio of 1,088.78, a P/E/G ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45. The firm has a 50-day moving average of $92.58 and a 200-day moving average of $86.14. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.29 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. Citigroup started coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. The Goldman Sachs Group raised their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. BMO Capital Markets raised their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.